secwatch.observer — SEC 8-K summary
======================================

Issuer:     TScan Therapeutics, Inc. (TCRX)
CIK:        0001783328
Form:       8-K
Filed at:   2022-11-09T23:59:59+00:00
Accession:  0000950170-22-023503
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TScan Therapeutics reports Q3 net loss of $16.2M and cash of $137.3M
--------------------------------------------------------------------

- Net loss $16.2M vs $15.8M YoY; revenue $3.4M vs $2.4M YoY.
- Cash and equivalents $137.3M; closed $60M debt facility with K2 HealthVentures, initial $30M drawn.
- Phase 1 umbrella trial for TSC-100/101 enrolling; pre-IND meeting with FDA completed for solid tumors.
- Plan IND submissions for MAGE-A1 TCRs by end 2022; HPV and PRAME INDs by H1 2023.
- Virtual investor event Nov 14, 2022 to detail solid tumor clinical development plans.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1783328/000095017022023503/0000950170-22-023503-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1783328/000095017022023503/tcrx-20221109.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-023503

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer